Evidence map›Paper›PMID 35364330›Full record

ArticleClinical immunology (Orlando, Fla.)2022

Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19.

Naoki Kaneko, Julie Boucau, Hsiao-Hsuan Kuo, Cory Perugino, Vinay S Mahajan, Jocelyn R Farmer, Hang Liu, Thomas J Diefenbach, Alicja Piechocka-Trocha, Kristina Lefteri and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Cytotoxic CD4+ T Cells Are Induced during Infection with Chlamydia trachomatis.Journal of immunology (Baltimore, Md. : 1950) · 2024
    Article
  13. Article
  14. Immune dysregulation in immunoglobulin G4-related disease.The Japanese dental science review · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. T cells in health and disease.Signal transduction and targeted therapy · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Naoki KanekoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Julie BoucauRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Hsiao-Hsuan KuoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Cory PeruginoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Rheumatology Allergy and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA.
Vinay S MahajanRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Jocelyn R FarmerRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Rheumatology Allergy and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA.
Hang LiuRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Thomas J DiefenbachRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Alicja Piechocka-TrochaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA.
Kristina LefteriRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Michael T WaringRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Katherine R PremoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA; Department of Biology and Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Gaurav GaihaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Robert F PaderaDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address: rpadera@rics.bwh.harvard.edu.
Shiv PillaiRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: pillai@helix.mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USBrigham and Women's Hospital · USHoward Hughes Medical Institute · USMassachusetts General Hospital · USMassachusetts Institute of Technology · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
The importance of the IgG4 glycome in IgG4-related disease(s)U19AI110495 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SHIV Subramaniam PILLAI · 2014 to 2026
$7.9M
NIAID NIH HHS U19 AI110495NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

Many studies have been performed in severe COVID-19 on immune cells in the circulation and on cells obtained by bronchoalveolar lavage. Most studies have tended to provide relative information rather than a quantitative view, and it is a combination of approaches by various groups that is helping the field build a picture of the mechanisms that drive severe lung disease. Approaches employed to date have not revealed information on lung parenchymal T cell subsets in severe COVID-19. Therefore, we sought to examine early and late T cell subset alterations in the lungs and draining lymph nodes in severe COVID-19 using a rapid autopsy protocol and quantitative imaging approaches. Here, we have established that cytotoxic CD4+ T cells (CD4 + CTLs) increase in the lungs, draining lymph nodes and blood as COVID-19 progresses. CD4 + CTLs are prominently expanded in the lung parenchyma in severe COVID-19. In contrast CD8+ T cells are not prominent, exhibit increased PD-1 expression, and no obvious increase is seen in the number of Granzyme B+ CD8+ T cells in the lung parenchyma in severe COVID-19. Based on quantitative evidence for re-activation in the lung milieu, CD4 + CTLs may be as likely to drive viral clearance as CD8+ T cells and may also be contributors to lung inflammation and eventually to fibrosis in severe COVID-19.

Indexed as

CD4-Positive T-LymphocytesCOVID-19CD8-Positive T-LymphocytesHumansLungT-Lymphocytes, CytotoxicT-Lymphocyte SubsetsCD8+ T cellsCOVID-19Cytotoxic CD4+ T cells

Identifiers

PMID35364330
PMCPMC8961941
OpenAlexW4220888679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.